Developer docs
API playgroundTry for free, no card

Search company profiles

Holostem

Full company profile

uuid005x236

Namestring
Holostem
Legal namestring
Holostem S.r.l. a Socio Unico
Websiteurl
holostem.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Holostem S.r.l. a Socio Unico is an Italian biotechnology company founded in 2008 as a spin-off of the University of Modena and Reggio Emilia (Unimore), with investment from Chiesi Farmaceutici. The company develops, produces, registers, and distributes Advanced Therapy Medicinal Products (ATMPs) based on cultured epithelial stem cells, for both cell therapy and gene therapy indications. It is headquartered within the Centro di Medicina Rigenerativa Stefano Ferrari at Unimore in Modena, Italy, operates a GMP-certified manufacturing facility, and employs between 11 and 50 staff.

Holostem's commercial product is Holoclar, the first stem cell-based medicinal product formally approved in the Western world, consisting of ex-vivo reconstructed autologous human corneal epithelium used to treat moderate to severe Limbal Stem Cell Deficiency (LSCD) caused by ocular burns. Holoclar received conditional European marketing authorization in February 2015 and was upgraded to full authorization in 2024 in both the EU (Decision No. 1299/2024) and the UK (MHRA, March 2024). A US equivalent (GPLSCD01) holds FDA orphan drug designation. The pipeline includes Hologene 5, a Phase II/III combined cell and gene therapy for Junctional Epidermolysis Bullosa using transgenic keratinocytes carrying the LAMB3 gene. Long-term clinical evidence spans 223 patients and 10+ years of follow-up, with success rates of 51-77%.

Holostem's go-to-market is a specialized enterprise field-sales model: Holoclar is distributed directly from the Modena GMP facility to authorized treatment centers across ~20 sites in 10+ European countries, with EMA-mandated surgeon training and 36-hour shelf-life logistics. In Italy, only two centers (San Raffaele Milano and San Giovanni Addolorata Roma) are currently authorized; the UK is served via a Newcastle Hospitals NHS partnership, and the Czech Republic via Medasol. In June 2022, the Board approved a transition from a for-profit S.r.l. to a nonprofit foundation, indicating a strategic shift toward patient access over profit maximization. The company retains Chiesi as a key strategic partner, though marketing authorization was transferred from Chiesi to Holostem in 2020.

Short descriptiontext

Holostem is an Italian biotech company developing, producing, and distributing Advanced Therapy Medicinal Products based on epithelial stem cells, commercially marketing Holoclar (the first approved stem-cell therapy for Limbal Stem Cell Deficiency) and advancing gene therapies for Epidermolysis Bullosa across European treatment centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersModena, Italy
HQ citystring
Modena
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
advanced therapy medicinal products, autologous cell therapy, regenerative medicine, cell and gene therapy, stem cell therapies
Industry1 code
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales (Holoclar)
TypeOne Time License
Description

Holoclar is produced and distributed by Holostem, with Chiesi holding marketing authorization in Europe. The product is distributed to authorized treatment centers across European countries. Holoclar received full marketing authorization in EU and UK in 2024, transitioning from conditional status.

holostem.com
2Gene Therapy Development
TypeOne Time License
Description

Development of gene therapy products for Epidermolysis Bullosa (Hologene 5) and other genodermatoses. Revenue may come from clinical trial partnerships, regulatory approvals, and future commercialization.

holostem.com
3Foundation Model Transition
TypeLicensing Royalties
Description

In June 2022, Holostem began transitioning from a for-profit company to a non-profit foundation, which may change the revenue model structure to focus on patient access rather than profit maximization.

holostem.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Holostem develops, produces, registers, and distributes Advanced Therapy Medicinal Products (ATMPs) based on cultured epithelial stem cells for cell and gene therapy. Its lead commercial product, Holoclar, is the first stem cell-based medicinal product approved in the Western world (EU 2015, UK 2024), consisting of autologous cultivated corneal epithelium used to treat Limbal Stem Cell Deficiency from ocular burns. The company also develops gene therapies for Epidermolysis Bullosa using transgenic epidermal cultures.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 77% success rate measured by ophthalmologists in HOLOCORE clinical study
+4 more records
Product overview1 text field

Holostem is a biotech company specializing in advanced therapy medicinal products (ATMPs) based on cultured epithelial stem cells for cell and gene therapy. The core product portfolio includes Holoclar (approved cell therapy for Limbal Stem Cell Deficiency), GPLSCD01 (US orphan drug designated equivalent), Hologene 5 (gene therapy for Epidermolysis Bullosa in clinical trials), cell therapy for corneal surface regeneration, and gene therapy for Epidermolysis Bullosa. All products utilize autologous stem cell approaches combined with gene therapy where applicable.

Product and service3 records
1Holoclar
CategoryCell Therapy / Advanced Therapy Medicinal Product (ATMP)
Description

Advanced cell therapy medicinal product consisting of ex-vivo reconstructed autologous human corneal epithelium containing limbal stem cells, produced from a 1-2mm² biopsy of the patient's undamaged limbus and cultivated to form a graft that is transplanted onto the damaged eye. Used to treat moderate to severe Limbal Stem Cell Deficiency (LSCD) caused by physical or chemical eye burns in adult patients.

2GPLSCD01
CategoryCell Therapy / Advanced Therapy Medicinal Product (ATMP)
Description

Experimental cell therapy product (known as Holoclar in the EU) consisting of autologous expanded ex-vivo human corneal epithelial cells for the treatment of Limbal Stem Cell Deficiency. Developed for the US market where it has received FDA orphan drug designation but is not yet approved.

3Hologene 5 - Gene Therapy for Epidermolysis Bullosa
CategoryGene Therapy / Combined Cell and Gene Therapy
Description

Combined cell and gene therapy product for treatment of Junctional Epidermolysis Bullosa (JEB) caused by LAMB3 mutations. Uses transgenic keratinocytes and epidermal stem cells genetically corrected with gamma-retroviral vector carrying functional human LAMB3 cDNA to restore functional epidermis. Approximately 80% body surface area (about 1 square meter) successfully treated in the landmark patient case published in Nature (2017) with 5+ years stable transgenic epidermis confirmed in New England Journal of Medicine (2021).

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-15
Description

Strategic partnership to expand access to advanced therapies for ocular pathologies. The agreement includes strengthening the network of centers administering Holoclar, sharing expertise for medical training and research on stem cells applied to ophthalmology. This represents a virtuous example of public-private synergy with patients at the center.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-24
Description

Partnership to make Holoclar available to patients at specialist centers across England. Newcastle pharmacists worked extensively with Holostem to overcome import challenges and develop regulatory authorizations. The partnership enabled NHS access through 4 approved treatment sites.

3Northern Alliance Advanced Therapies Treatment Centre
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2022-06-24
Description

Facilitated the partnership between Newcastle Hospitals and Holostem, working to support the use of advanced therapies and ensure access for NHS patients.

holostem.com
4Azienda Ospedaliero-Universitaria di Modena
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-21
Description

Established a PDTA (Percorso Diagnostico Terapeutico Assistenziale) for Epidermolysis Bullosa integrating over 30 specialties. The center is led by Prof. Cristina Magnoni and serves patients from across Italy. Prof. Michele De Luca's research group provides ongoing research contributions.

holostem.com
5Medasol (Bluedil International)
Strategic tierSupportingTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-05-12
Description

Medasol provides market access and commercial services for Holoclar in Czech Republic. With 20 years of experience commercializing orphan drugs, they support pharmaceutical and biotech companies in making innovative treatments available to patients with rare diseases.

holostem.com
6University Hospital Brno Eye Clinic
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-05-12
Description

Holoclar became available in Czech Republic through the University Hospital Brno Eye Clinic, founded in 1990. The clinic specializes in anterior segment microsurgery including corneal transplants, vitreoretinal surgery, ocular traumatology, and strabismus surgery.

holostem.com
7Le Ali di Camilla Association
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2020-01-23
Description

Association promoting research and care for Epidermolysis Bullosa in Modena. Collaborated in organizing the EB Hub presentation and supports the overall EB patient community and research network.

holostem.com
8EB Hub
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-23
Description

A unique center at Policlinico di Modena serving as a meeting point for diagnosis, research, care, and innovative therapies for Epidermolysis Bullosa. Involves collaboration between Azienda Ospedaliera, University, Holostem, and patient associations.

holostem.com
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2015-02-20
Description

Chiesi Farmaceutici holds the European marketing authorization for Holoclar granted by the European Commission in 2015. Chiesi invested in certifying the Centro di Medicina Rigenerativa GMP facility and supported the product's regulatory pathway. In June 2020, Holostem signed an agreement for transfer of Holoclar marketing rights from Chiesi to Holostem.

10University of Modena and Reggio Emilia (Unimore)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2008-01-01
Description

Holostem is a university spin-off located within the Centro di Medicina Rigenerativa Stefano Ferrari at Unimore. Prof. Michele De Luca serves as Director of the Center and Scientific Director of Holostem. The collaboration enables transfer of research findings to clinical application and patient access to advanced therapies.

holostem.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Aurion Biotech is developing allogeneic corneal endothelial cell therapies for corneal edema and endothelial dysfunction. It is the closest direct peer to Holostem because both companies operate in autologous/allogeneic corneal cell therapy, target ophthalmic indications of the anterior segment of the eye, and rely on GMP cell-manufacturing platforms.

TypeBroad incumbent
Description

Regenxbio develops AAV-based gene therapy platforms with applications across ophthalmology (e.g., RGX-314) and other rare diseases. It is comparable to Holostem because both develop advanced therapy medicinal products targeting rare ocular indications using gene-therapy delivery technology.

TypeOthers
Description

Kala Pharmaceuticals is a specialty ophthalmic drug delivery company developing therapies for front- and back-of-the-eye diseases. It is thematically adjacent rather than directly competitive — both companies operate in ophthalmology, but Kala's approach is small-molecule drug delivery rather than cell or gene therapy.

TypeDirect peer
Description

jCyte develops human retinal progenitor cell therapies for retinal degenerative diseases including retinitis pigmentosa. It is comparable to Holostem as a clinical-stage cell therapy company focused on ophthalmology with autologous/semi-autologous cell therapy assets.

TypeDirect peer
Description

GenSight Biologics develops gene therapies for inherited retinal diseases and optic neuropathies. It is a direct peer because both companies are European-based, ophthalmology-focused advanced therapy developers combining cell or gene therapy approaches to address rare ocular indications.

TypeBroad incumbent
Description

Chiesi is the strategic shareholder and former marketing-authorization holder for Holoclar and operates broadly in rare diseases, cell/gene therapy, and specialty pharma. It is comparable as the incumbent commercial partner and broader industry player supporting Holostem's commercialization rather than as a competing technology developer.

TypeEmerging player
Description

Capricor develops cell-derived extracellular vesicle and cell therapy products (e.g., CAP-1002) for Duchenne muscular dystrophy and other rare diseases. It is comparable as an emerging regenerative-medicine player addressing rare diseases with cell-based therapeutics.

TypeEmerging player
Description

Adaptimmune develops engineered T-cell receptor (TCR-T) cell therapies for solid tumors. It is comparable as an emerging cell therapy company using patient-derived cellular products with gene-engineering steps, sharing Holostem's autologous + gene-modification platform approach.

TypeEmerging player
Description

Lineage Cell Therapeutics develops allogeneic cell transplant therapies for neurological and ophthalmic indications, including OpRegen for dry age-related macular degeneration. It is comparable to Holostem because both companies operate cell therapy platforms targeting ophthalmic indications with regenerative mechanisms.

TypeBroad incumbent
Description

Iovance is a commercial-stage cell therapy company developing tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. It is comparable as a large-scale autologous cell therapy developer with established GMP manufacturing capabilities for patient-derived cellular products.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Holostem

Regenerative Medicineholostem.com

Holostem is an Italian biotech company developing, producing, and distributing Advanced Therapy Medicinal Products based on epithelial stem cells, commercially marketing Holoclar (the first approved stem-cell therapy for Limbal Stem Cell Deficiency) and advancing gene therapies for Epidermolysis Bullosa across European treatment centers.

What Holostem does

Holostem S.r.l. a Socio Unico is an Italian biotechnology company founded in 2008 as a spin-off of the University of Modena and Reggio Emilia (Unimore), with investment from Chiesi Farmaceutici. The company develops, produces, registers, and distributes Advanced Therapy Medicinal Products (ATMPs) based on cultured epithelial stem cells, for both cell therapy and gene therapy indications. It is headquartered within the Centro di Medicina Rigenerativa Stefano Ferrari at Unimore in Modena, Italy, operates a GMP-certified manufacturing facility, and employs between 11 and 50 staff.

Holostem's commercial product is Holoclar, the first stem cell-based medicinal product formally approved in the Western world, consisting of ex-vivo reconstructed autologous human corneal epithelium used to treat moderate to severe Limbal Stem Cell Deficiency (LSCD) caused by ocular burns. Holoclar received conditional European marketing authorization in February 2015 and was upgraded to full authorization in 2024 in both the EU (Decision No. 1299/2024) and the UK (MHRA, March 2024). A US equivalent (GPLSCD01) holds FDA orphan drug designation. The pipeline includes Hologene 5, a Phase II/III combined cell and gene therapy for Junctional Epidermolysis Bullosa using transgenic keratinocytes carrying the LAMB3 gene. Long-term clinical evidence spans 223 patients and 10+ years of follow-up, with success rates of 51-77%.

Holostem's go-to-market is a specialized enterprise field-sales model: Holoclar is distributed directly from the Modena GMP facility to authorized treatment centers across ~20 sites in 10+ European countries, with EMA-mandated surgeon training and 36-hour shelf-life logistics. In Italy, only two centers (San Raffaele Milano and San Giovanni Addolorata Roma) are currently authorized; the UK is served via a Newcastle Hospitals NHS partnership, and the Czech Republic via Medasol. In June 2022, the Board approved a transition from a for-profit S.r.l. to a nonprofit foundation, indicating a strategic shift toward patient access over profit maximization. The company retains Chiesi as a key strategic partner, though marketing authorization was transferred from Chiesi to Holostem in 2020.

Holostem firmographics

Firmographics
Name
Holostem
Legal name
Holostem S.r.l. a Socio Unico
Website
https://holostem.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Holostem is an Italian biotech company developing, producing, and distributing Advanced Therapy Medicinal Products based on epithelial stem cells, commercially marketing Holoclar (the first approved stem-cell therapy for Limbal Stem Cell Deficiency) and advancing gene therapies for Epidermolysis Bullosa across European treatment centers.
Ownership category
akta.pro rank

Holostem industry classification

Industry
Product category
Regenerative Medicine
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Advanced therapy medicinal products
  • Autologous cell therapy
  • Regenerative medicine
  • Cell and gene therapy
  • Stem cell therapies

Where Holostem is headquartered

Location

Headquarters

HQ city
Modena
HQ country
Italy
HQ region
Europe

Offices1 record

Markets served

Holostem business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales (Holoclar): Holoclar is produced and distributed by Holostem, with Chiesi holding marketing authorization in Europe. The product is distributed to authorized treatment centers across European countries. Holoclar received full marketing authorization in EU and UK in 2024, transitioning from conditional status.
  2. Gene Therapy Development: Development of gene therapy products for Epidermolysis Bullosa (Hologene 5) and other genodermatoses. Revenue may come from clinical trial partnerships, regulatory approvals, and future commercialization.
  3. Foundation Model Transition: In June 2022, Holostem began transitioning from a for-profit company to a non-profit foundation, which may change the revenue model structure to focus on patient access rather than profit maximization.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Holostem product offering

Product offering

Core offering

Holostem develops, produces, registers, and distributes Advanced Therapy Medicinal Products (ATMPs) based on cultured epithelial stem cells for cell and gene therapy. Its lead commercial product, Holoclar, is the first stem cell-based medicinal product approved in the Western world (EU 2015, UK 2024), consisting of autologous cultivated corneal epithelium used to treat Limbal Stem Cell Deficiency from ocular burns. The company also develops gene therapies for Epidermolysis Bullosa using transgenic epidermal cultures.

Product overview

Holostem is a biotech company specializing in advanced therapy medicinal products (ATMPs) based on cultured epithelial stem cells for cell and gene therapy. The core product portfolio includes Holoclar (approved cell therapy for Limbal Stem Cell Deficiency), GPLSCD01 (US orphan drug designated equivalent), Hologene 5 (gene therapy for Epidermolysis Bullosa in clinical trials), cell therapy for corneal surface regeneration, and gene therapy for Epidermolysis Bullosa. All products utilize autologous stem cell approaches combined with gene therapy where applicable.

Differentiator

Problem solved

Functional benefit

Products and services

  • Holoclar Advanced cell therapy medicinal product consisting of ex-vivo reconstructed autologous human corneal epithelium containing limbal stem cells, produced from a 1-2mm² biopsy of the patient's undamaged limbus and cultivated to form a graft that is transplanted onto the damaged eye. Used to treat moderate to severe Limbal Stem Cell Deficiency (LSCD) caused by physical or chemical eye burns in adult patients.
  • GPLSCD01 Experimental cell therapy product (known as Holoclar in the EU) consisting of autologous expanded ex-vivo human corneal epithelial cells for the treatment of Limbal Stem Cell Deficiency. Developed for the US market where it has received FDA orphan drug designation but is not yet approved.
  • Hologene 5 - Gene Therapy for Epidermolysis Bullosa Combined cell and gene therapy product for treatment of Junctional Epidermolysis Bullosa (JEB) caused by LAMB3 mutations. Uses transgenic keratinocytes and epidermal stem cells genetically corrected with gamma-retroviral vector carrying functional human LAMB3 cDNA to restore functional epidermis. Approximately 80% body surface area (about 1 square meter) successfully treated in the landmark patient case published in Nature (2017) with 5+ years stable transgenic epidermis confirmed in New England Journal of Medicine (2021).

Quantifiable outcome

  • 77% success rate measured by ophthalmologists in HOLOCORE clinical study
  • +4 more outcomes

Companies that use Holostem

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles1 record

Holostem technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Holostem partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and supporting.

  • Fondazione Banca degli Occhi del VenetocoreStrategic or Co-development Partner · 15 October 2025Strategic partnership to expand access to advanced therapies for ocular pathologies. The agreement includes strengthening the network of centers administering Holoclar, sharing expertise for medical training and research on stem cells applied to ophthalmology. This represents a virtuous example of public-private synergy with patients at the center.
  • Newcastle Hospitals NHS Foundation TrustcoreStrategic or Co-development Partner · 24 June 2022Partnership to make Holoclar available to patients at specialist centers across England. Newcastle pharmacists worked extensively with Holostem to overcome import challenges and develop regulatory authorizations. The partnership enabled NHS access through 4 approved treatment sites.
  • Northern Alliance Advanced Therapies Treatment CentresupportingStrategic or Co-development Partner · 24 June 2022Facilitated the partnership between Newcastle Hospitals and Holostem, working to support the use of advanced therapies and ensure access for NHS patients.
  • Azienda Ospedaliero-Universitaria di ModenacoreStrategic or Co-development Partner · 21 May 2022Established a PDTA (Percorso Diagnostico Terapeutico Assistenziale) for Epidermolysis Bullosa integrating over 30 specialties. The center is led by Prof. Cristina Magnoni and serves patients from across Italy. Prof. Michele De Luca's research group provides ongoing research contributions.
  • Medasol (Bluedil International)supportingChannel Partner/ Reseller/ Distributor · 12 May 2021Medasol provides market access and commercial services for Holoclar in Czech Republic. With 20 years of experience commercializing orphan drugs, they support pharmaceutical and biotech companies in making innovative treatments available to patients with rare diseases.
  • University Hospital Brno Eye CliniccoreStrategic or Co-development Partner · 12 May 2021Holoclar became available in Czech Republic through the University Hospital Brno Eye Clinic, founded in 1990. The clinic specializes in anterior segment microsurgery including corneal transplants, vitreoretinal surgery, ocular traumatology, and strabismus surgery.
  • Le Ali di Camilla AssociationsupportingStrategic or Co-development Partner · 23 January 2020Association promoting research and care for Epidermolysis Bullosa in Modena. Collaborated in organizing the EB Hub presentation and supports the overall EB patient community and research network.
  • EB HubcoreStrategic or Co-development Partner · 23 January 2020A unique center at Policlinico di Modena serving as a meeting point for diagnosis, research, care, and innovative therapies for Epidermolysis Bullosa. Involves collaboration between Azienda Ospedaliera, University, Holostem, and patient associations.
  • Chiesi FarmaceuticicoreGTM or Marketing Partner · 20 February 2015Chiesi Farmaceutici holds the European marketing authorization for Holoclar granted by the European Commission in 2015. Chiesi invested in certifying the Centro di Medicina Rigenerativa GMP facility and supported the product's regulatory pathway. In June 2020, Holostem signed an agreement for transfer of Holoclar marketing rights from Chiesi to Holostem.
  • University of Modena and Reggio Emilia (Unimore)coreStrategic or Co-development Partner · 1 January 2008Holostem is a university spin-off located within the Centro di Medicina Rigenerativa Stefano Ferrari at Unimore. Prof. Michele De Luca serves as Director of the Center and Scientific Director of Holostem. The collaboration enables transfer of research findings to clinical application and patient access to advanced therapies.

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

Holostem competitors and assessment

Company assessment

Direct peers

  • Aurion Biotech: Aurion Biotech is developing allogeneic corneal endothelial cell therapies for corneal edema and endothelial dysfunction. It is the closest direct peer to Holostem because both companies operate in autologous/allogeneic corneal cell therapy, target ophthalmic indications of the anterior segment of the eye, and rely on GMP cell-manufacturing platforms.
  • jCyte: jCyte develops human retinal progenitor cell therapies for retinal degenerative diseases including retinitis pigmentosa. It is comparable to Holostem as a clinical-stage cell therapy company focused on ophthalmology with autologous/semi-autologous cell therapy assets.
  • GenSight Biologics: GenSight Biologics develops gene therapies for inherited retinal diseases and optic neuropathies. It is a direct peer because both companies are European-based, ophthalmology-focused advanced therapy developers combining cell or gene therapy approaches to address rare ocular indications.

Broad incumbents

  • Regenxbio: Regenxbio develops AAV-based gene therapy platforms with applications across ophthalmology (e.g., RGX-314) and other rare diseases. It is comparable to Holostem because both develop advanced therapy medicinal products targeting rare ocular indications using gene-therapy delivery technology.
  • Chiesi Farmaceutici: Chiesi is the strategic shareholder and former marketing-authorization holder for Holoclar and operates broadly in rare diseases, cell/gene therapy, and specialty pharma. It is comparable as the incumbent commercial partner and broader industry player supporting Holostem's commercialization rather than as a competing technology developer.
  • Iovance Biotherapeutics: Iovance is a commercial-stage cell therapy company developing tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. It is comparable as a large-scale autologous cell therapy developer with established GMP manufacturing capabilities for patient-derived cellular products.

Others

  • Kala Pharmaceuticals: Kala Pharmaceuticals is a specialty ophthalmic drug delivery company developing therapies for front- and back-of-the-eye diseases. It is thematically adjacent rather than directly competitive — both companies operate in ophthalmology, but Kala's approach is small-molecule drug delivery rather than cell or gene therapy.

Emerging players

  • Capricor Therapeutics: Capricor develops cell-derived extracellular vesicle and cell therapy products (e.g., CAP-1002) for Duchenne muscular dystrophy and other rare diseases. It is comparable as an emerging regenerative-medicine player addressing rare diseases with cell-based therapeutics.
  • Adaptimmune: Adaptimmune develops engineered T-cell receptor (TCR-T) cell therapies for solid tumors. It is comparable as an emerging cell therapy company using patient-derived cellular products with gene-engineering steps, sharing Holostem's autologous + gene-modification platform approach.
  • Lineage Cell Therapeutics: Lineage Cell Therapeutics develops allogeneic cell transplant therapies for neurological and ophthalmic indications, including OpRegen for dry age-related macular degeneration. It is comparable to Holostem because both companies operate cell therapy platforms targeting ophthalmic indications with regenerative mechanisms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Holostem social profiles

Digital presence

Holostem financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Holostem leadership team

Management profile

Number of profiles

Profiles5 records

Holostem funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Holostem M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Holostem

What does Holostem do?

Holostem develops, produces, registers, and distributes Advanced Therapy Medicinal Products (ATMPs) based on cultured epithelial stem cells for cell and gene therapy. Its lead commercial product, Holoclar, is the first stem cell-based medicinal product approved in the Western world (EU 2015, UK 2024), consisting of autologous cultivated corneal epithelium used to treat Limbal Stem Cell Deficiency from ocular burns. The company also develops gene therapies for Epidermolysis Bullosa using transgenic epidermal cultures.

Is Holostem a public or private company?

Holostem is a private company. It is classified as corporate owned and is currently operating.

When was Holostem founded?

Holostem was founded in 2008. It employs 11 to 50 people.

Where is Holostem based?

Holostem is headquartered in Modena, Italy, in the Europe region.

How does Holostem make money?

Three revenue lines are on record. Pharmaceutical Product Sales (Holoclar) is the primary driver. The others are gene Therapy Development and foundation Model Transition.

Who are Holostem's main competitors?

Direct peers on record are Aurion Biotech, jCyte and GenSight Biologics. Broad incumbents are Regenxbio, Chiesi Farmaceutici and Iovance Biotherapeutics. Kala Pharmaceuticals is listed as an others. Emerging players are Capricor Therapeutics, Adaptimmune and Lineage Cell Therapeutics.

Does Holostem have an API?

No public API is recorded for Holostem.

What industry is Holostem in?

Holostem's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooEurope Cell Sheet-based Gene Therapy Market Analysis and Forecast, 2025-2035 - Favorable Regulatory Framework Under EMA's Advanced Therapy Medicinal Products (ATMP) PathwayEurope's cell sheet-based gene therapy market is projected to grow from $219.6 million in 2024 to $926 million by 2035, a CAGR of 13.98%. The market is driven by EMA's ATMP pathway and biotech leaders like Foundation ENEA Tech Biomedical, which acquired Holostem S.r.l. in December 2023.GlobeNewswireEurope Cell Sheet-based Gene Therapy Market Analysis and Forecast, 2025-2035 - Favorable Regulatory Framework Under EMA's Advanced Therapy Medicinal Products (ATMP) PathwayThe Europe cell sheet-based gene therapy market is projected to grow from $219.6 million in 2024 to $926 million by 2035, representing a compound annual growth rate of 13.98%. Foundation ENEA Tech Biomedical emerged as a significant market force following its acquisition of Holostem S.r.l. in December 2023, with Holostem being the first European biotech company focused on epithelial stem cell-based breakthrough medicines including the Holoclar treatment for corneal regeneration. The EMA's Advanced Therapy Medicinal Products framework and public-private partnerships are positioning Europe as a hub for cell sheet-based gene therapy development targeting complex tissue-specific and epithelial disorders.IttbiomedBiotech Enea Foundation acquires business unit Holostem Terapie AvanzateThe Enea Tech and Biomedical Foundation has formally acquired Holostem, a business unit of the biotech company Holostem Terapie Avanzate. The acquisition aims to establish an innovation hub for cell and gene therapy research while ensuring continued access to life-saving treatments for patients with rare diseases like epidermolysis bullosa.